Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,533
archived clinical trials in
Chronic Obstructive Pulmonary Disease

OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated:  12/1/2016
ALTANA Pharma
mi
from
Cities in Wisconsin, WI
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated: 12/1/2016
ALTANA Pharma
mi
from
Cities in Wisconsin, WI
Click here to add this to my saved trials
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated:  12/1/2016
ALTANA Pharma
mi
from
Cities in Canada,
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated: 12/1/2016
ALTANA Pharma
mi
from
Cities in Canada,
Click here to add this to my saved trials
BEAM COPD: Breathing, Education, Awareness and Movement in Chronic Obstructive Pulmonary Disease (COPD)
BEAM COPD: Breathing, Education, Awareness and Movement in Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  12/14/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
BEAM COPD: Breathing, Education, Awareness and Movement in Chronic Obstructive Pulmonary Disease (COPD)
BEAM COPD: Breathing, Education, Awareness and Movement in Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 12/14/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
BEAM COPD: Breathing, Education, Awareness and Movement in Chronic Obstructive Pulmonary Disease (COPD)
BEAM COPD: Breathing, Education, Awareness and Movement in Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  12/14/2016
VA Healthcare System
mi
from
Boston, MA
BEAM COPD: Breathing, Education, Awareness and Movement in Chronic Obstructive Pulmonary Disease (COPD)
BEAM COPD: Breathing, Education, Awareness and Movement in Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 12/14/2016
VA Healthcare System
mi
from
Boston, MA
Click here to add this to my saved trials
Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients
Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients
Status: Enrolling
Updated:  12/15/2016
Lsu Health Sciences Center
mi
from
New Orleans, LA
Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients
Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients
Status: Enrolling
Updated: 12/15/2016
Lsu Health Sciences Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Birmingham, AL
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
New Haven, CT
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Chicago, IL
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Iowa City, IA
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Baltimore, MD
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Chapel Hill, NC
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Cleveland, OH
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Philadelphia, PA
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Galveston, TX
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Galveston, TX
Click here to add this to my saved trials
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  12/19/2016
mi
from
Calgary,
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 12/19/2016
mi
from
Calgary,
Click here to add this to my saved trials
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated:  12/20/2016
GSK Investigational Site
mi
from
Birmingham, AL
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated: 12/20/2016
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated:  12/20/2016
GSK Investigational Site
mi
from
Denver, CO
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated: 12/20/2016
GSK Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated:  12/20/2016
GSK Investigational Site
mi
from
Iowa City, IA
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated: 12/20/2016
GSK Investigational Site
mi
from
Iowa City, IA
Click here to add this to my saved trials
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated:  12/20/2016
GSK Investigational Site
mi
from
Oaks, PA
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated: 12/20/2016
GSK Investigational Site
mi
from
Oaks, PA
Click here to add this to my saved trials
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated:  12/20/2016
GSK Investigational Site
mi
from
Philadelphia, PA
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated: 12/20/2016
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated:  12/20/2016
GSK Investigational Site
mi
from
Spartanburg, SC
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated: 12/20/2016
GSK Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated:  12/20/2016
GSK Investigational Site
mi
from
Frankfurt,
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated: 12/20/2016
GSK Investigational Site
mi
from
Frankfurt,
Click here to add this to my saved trials
Functional Applications of Hyperpolarized 129Xe MRI
Functional Applications of Hyperpolarized 129Xe MRI
Status: Enrolling
Updated:  12/28/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Functional Applications of Hyperpolarized 129Xe MRI
Functional Applications of Hyperpolarized 129Xe MRI
Status: Enrolling
Updated: 12/28/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Cardiac Hemodynamics in Overlap Syndrome (COPD With Obstructive Sleep Apnea)
Comparison of Effects of Bi-level Positive Airway Pressure Therapy and Nocturnal Oxygen Therapy on Right and Left Ventricular Hemodynamics in Overlap Syndrome (Co-existent Chronic Obstructive Airway Disease and Obstructive Sleep Apnea)
Status: Enrolling
Updated:  1/11/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Cardiac Hemodynamics in Overlap Syndrome (COPD With Obstructive Sleep Apnea)
Comparison of Effects of Bi-level Positive Airway Pressure Therapy and Nocturnal Oxygen Therapy on Right and Left Ventricular Hemodynamics in Overlap Syndrome (Co-existent Chronic Obstructive Airway Disease and Obstructive Sleep Apnea)
Status: Enrolling
Updated: 1/11/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Cardiac Hemodynamics in Overlap Syndrome (COPD With Obstructive Sleep Apnea)
Comparison of Effects of Bi-level Positive Airway Pressure Therapy and Nocturnal Oxygen Therapy on Right and Left Ventricular Hemodynamics in Overlap Syndrome (Co-existent Chronic Obstructive Airway Disease and Obstructive Sleep Apnea)
Status: Enrolling
Updated:  1/11/2017
Massachussets General Hospital
mi
from
Boston, MA
Cardiac Hemodynamics in Overlap Syndrome (COPD With Obstructive Sleep Apnea)
Comparison of Effects of Bi-level Positive Airway Pressure Therapy and Nocturnal Oxygen Therapy on Right and Left Ventricular Hemodynamics in Overlap Syndrome (Co-existent Chronic Obstructive Airway Disease and Obstructive Sleep Apnea)
Status: Enrolling
Updated: 1/11/2017
Massachussets General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Mobile, AL
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Mobile, AL
Click here to add this to my saved trials
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Wheat Ridge, CO
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Wheat Ridge, CO
Click here to add this to my saved trials
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Biddeford, ME
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Biddeford, ME
Click here to add this to my saved trials
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
St. Louis, MO
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Summit, NJ
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Summit, NJ
Click here to add this to my saved trials
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Medford, OR
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Medford, OR
Click here to add this to my saved trials
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Erie, PA
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Erie, PA
Click here to add this to my saved trials
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Greenville, SC
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Spartanburg, SC
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Johnson City, TN
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Johnson City, TN
Click here to add this to my saved trials
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
San Antonio, TX
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Spokane, WA
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Spokane, WA
Click here to add this to my saved trials
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated:  2/2/2017
GSK Investigational Site
mi
from
Phoenix, AZ
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated: 2/2/2017
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated:  2/2/2017
GSK Investigational Site
mi
from
Hollywood, FL
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated: 2/2/2017
GSK Investigational Site
mi
from
Hollywood, FL
Click here to add this to my saved trials
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated:  2/2/2017
GSK Investigational Site
mi
from
Baltimore, MD
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated: 2/2/2017
GSK Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated:  2/2/2017
GSK Investigational Site
mi
from
Charlotte, NC
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated: 2/2/2017
GSK Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated:  2/2/2017
GSK Investigational Site
mi
from
Gastonia, NC
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated: 2/2/2017
GSK Investigational Site
mi
from
Gastonia, NC
Click here to add this to my saved trials
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated:  2/2/2017
GSK Investigational Site
mi
from
Easley, SC
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated: 2/2/2017
GSK Investigational Site
mi
from
Easley, SC
Click here to add this to my saved trials
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated:  2/2/2017
GSK Investigational Site
mi
from
Mt. Pleasant, SC
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated: 2/2/2017
GSK Investigational Site
mi
from
Mt. Pleasant, SC
Click here to add this to my saved trials
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated:  2/2/2017
GSK Investigational Site
mi
from
Seneca, SC
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated: 2/2/2017
GSK Investigational Site
mi
from
Seneca, SC
Click here to add this to my saved trials
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated:  2/2/2017
GSK Investigational Site
mi
from
McKinney, TX
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated: 2/2/2017
GSK Investigational Site
mi
from
McKinney, TX
Click here to add this to my saved trials
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated:  2/2/2017
GSK Investigational Site
mi
from
Grove City, OH
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated: 2/2/2017
GSK Investigational Site
mi
from
Grove City, OH
Click here to add this to my saved trials
Cholecalciferol Supplementation in Strengthening Inspiratory Muscles in Cholecalciferol-Deficient Patients With Chronic Obstructive Pulmonary Disease
Effect of Once Daily Oral Vitamin D3 Supplementation on Inspiratory Muscle Strength in Vitamin D3-Deficient COPD Patients
Status: Enrolling
Updated:  2/14/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Cholecalciferol Supplementation in Strengthening Inspiratory Muscles in Cholecalciferol-Deficient Patients With Chronic Obstructive Pulmonary Disease
Effect of Once Daily Oral Vitamin D3 Supplementation on Inspiratory Muscle Strength in Vitamin D3-Deficient COPD Patients
Status: Enrolling
Updated: 2/14/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Staccato Loxapine Pulmonary Safety in Patients With COPD
Pulmonary Safety of Staccato® Loxapine for Inhalation in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  3/13/2017
Spartanburg Medical Research
mi
from
Spartanburg, SC
Staccato Loxapine Pulmonary Safety in Patients With COPD
Pulmonary Safety of Staccato® Loxapine for Inhalation in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 3/13/2017
Spartanburg Medical Research
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Adipose Derived Cells for Chronic Obstructive Pulmonary Disease
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  3/15/2017
US Stem Cell Clinic
mi
from
Sunrise, FL
Adipose Derived Cells for Chronic Obstructive Pulmonary Disease
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 3/15/2017
US Stem Cell Clinic
mi
from
Sunrise, FL
Click here to add this to my saved trials